SOLV
HealthcareSolventum Corporation · Medical - Care Facilities · $13B
What is Solventum Corporation?
Solventum Corporation is a healthcare company spun out of 3M, focused on developing and commercializing medical, dental, health information, and filtration solutions. Headquartered in Maplewood, Minnesota, it serves hospitals, clinicians, and healthcare systems worldwide.
Solventum generates revenue across four business segments. Its Medsurg segment covers advanced wound care, sterilization assurance, and surgical supplies. Dental Solutions provides orthodontic and restorative products. Health Information Systems delivers software for physician documentation, coding automation, and data visualization. The Purification and Filtration segment supplies filters, membranes, and purifiers used in healthcare and life sciences settings. Together, these segments serve a broad range of clinical and operational needs.
Solventum was incorporated in 2023 and began operating as an independent public company in 2024, based in Maplewood, Minnesota.
- Advanced wound care and I.V. site management products
- Dental brackets, aligners, and restorative cements
- Health information and coding automation software
- Purification filters, cartridges, and membranes
- Sterilization assurance and surgical supply solutions
Is SOLV a Good Stock to Buy?
UQS Score rates SOLV as Below Average overall, reflecting a mixed picture across its five quality pillars.
The Quality pillar earns a Good rating, suggesting the underlying business generates reasonably stable cash flows relative to its asset base. Valuation is rated Attractive, meaning the stock may be priced at a discount compared to its intrinsic characteristics — a potential entry point for patient investors.
Both the Moat and Growth pillars are rated Weak, indicating limited competitive differentiation and subdued near-term expansion prospects. These are meaningful headwinds for long-term compounding.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SOLV pay dividends?
No — Solventum Corporation does not currently pay a dividend.
Solventum does not currently pay a dividend. As a recently independent company still integrating its operations post-spin-off, capital is likely prioritized toward debt management, operational investment, and stabilizing its business segments rather than returning cash to shareholders through distributions.
When does SOLV report earnings?
Solventum reports earnings on a quarterly cadence, consistent with standard practice for US-listed large-cap equities.
As a newly public company, Solventum is still establishing its standalone financial track record. Investors should watch segment-level trends across Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration for signals of stabilization or growth.
For the most recent quarter's results and guidance, visit Solventum's investor relations page directly.
What if I invested in Solventum Corporation?
Based on Solventum Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
SOLV Long-term Outlook
With Growth and Moat pillars both rated Weak, Solventum's near-term fundamental outlook is cautious. The company faces the challenge of driving organic expansion across four distinct segments while managing the operational complexity of a recent corporate spin-off. The Attractive Valuation rating suggests the market may already be pricing in these headwinds, which could limit downside — but a re-rating upward would likely require demonstrated improvement in competitive positioning or revenue momentum.
Growth drivers
- Cross-segment synergies from integrating medical, dental, and software offerings
- Demand for health information systems as hospitals digitize clinical workflows
- Filtration and purification needs growing in life sciences and biopharma
Key risks
- Weak moat leaves segments exposed to competition from larger, more entrenched players
- Post-spin-off debt load and integration costs could weigh on free cash flow
- Slow organic growth across mature product lines in Medsurg and Dental
SOLV vs Peers
Solventum operates in a broad healthcare landscape and can be viewed alongside other large healthcare service and solutions providers.
Ensign focuses on post-acute care services rather than medical products, competing indirectly through its presence in the broader healthcare continuum.
UHS operates acute care and behavioral health hospitals, representing a service-delivery model distinct from Solventum's product and software focus.
Fresenius Medical Care specializes in dialysis products and services, overlapping with Solventum in filtration and purification technology markets.
Frequently Asked Questions
What does Solventum do?
Solventum is a healthcare company that develops and sells medical, dental, health information, and filtration products. It operates four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company serves hospitals, clinicians, dental practices, and life sciences customers globally.
Does SOLV pay dividends?
No, Solventum does not currently pay a dividend. As a recently spun-off company, it is focused on managing its balance sheet and investing in its core operations rather than distributing cash to shareholders at this stage.
When does SOLV report earnings?
Solventum reports on a quarterly cadence, as is standard for US-listed large-cap companies. For exact dates and the most recent results, check Solventum's investor relations page, where management also provides segment-level commentary.
Is SOLV a good stock to buy?
UQS Score rates SOLV as Below Average overall. The Valuation pillar is Attractive and Quality is Good, but Moat and Growth are both Weak. Whether it fits your portfolio depends on your risk tolerance and investment horizon. The full pillar breakdown is available to Pro members.
Is SOLV overvalued?
Based on the UQS Valuation pillar, SOLV is rated Attractive — suggesting it may be trading at a discount relative to its fundamental profile. However, an attractive price alone does not offset concerns around weak competitive moat and limited growth momentum.
How does SOLV compare to its competitors?
Solventum competes in a broad healthcare space alongside companies like Fresenius Medical Care, Universal Health Services, and The Ensign Group. Unlike pure-play service providers, Solventum's differentiation lies in its multi-segment product and software portfolio, though its Moat pillar rating suggests this differentiation is currently limited.
What is SOLV's market cap bracket?
Solventum is classified as a large-cap company. This places it among established healthcare businesses with significant revenue scale, though it is still early in its journey as an independent publicly traded entity.
Who founded Solventum?
Solventum was not founded in the traditional sense — it was spun off from 3M Company as an independent healthcare business. It was incorporated in 2023 and began trading publicly in 2024. More detail on its corporate history is available through Solventum's investor relations materials.
Is SOLV a long-term quality investment?
As a long-term quality indicator, SOLV's UQS profile presents a mixed picture. The Good Quality rating is a positive signal, but Weak Moat and Weak Growth suggest the company needs to demonstrate stronger competitive positioning before it can be considered a high-conviction long-term holding.
What is the main competitive advantage of Solventum?
Solventum's breadth across medical, dental, software, and filtration segments gives it cross-selling potential and diversified revenue streams. However, the UQS Moat pillar is currently rated Weak, indicating that this diversification has not yet translated into durable competitive advantages relative to sector peers.
What sector does SOLV belong to?
Solventum operates in the Healthcare sector. Within that sector, it spans medical devices, dental products, health IT software, and filtration technologies — making it a diversified healthcare solutions company rather than a single-category specialist.
Is SOLV a growth stock or value stock?
Based on the UQS pillar profile, SOLV leans toward value territory — the Valuation pillar is Attractive while the Growth pillar is Weak. This combination suggests the stock may appeal more to value-oriented investors than those seeking high-growth compounders.
Unlock Full SOLV Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare SOLV against sector peers side by side
- ✓See Growth and Moat pillar deep-dives
- ✓Get the full analyst-style quality assessment
- ✓Track score changes as new data is released
Pro Analysis
SOLV — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 48.5 | 68.8 | 32.0 | 17.8 | 39.2 | 92.3 | -2.0 |
| May 7, 2026 | 50.5 | 71.6 | 32.0 | 17.3 | 41.7 | 99.2 | -0.1 |
| Apr 26, 2026 | 50.6 | 71.6 | 32.0 | 17.3 | 41.7 | 100.0 | 0.0 |
| Apr 21, 2026 | 50.6 | 71.6 | 32.0 | 17.3 | 41.7 | 99.6 | +0.1 |
| Apr 19, 2026 | 50.5 | 71.6 | 32.0 | 17.3 | 41.7 | 99.6 | -0.1 |
| Apr 2, 2026 | 50.6 | 71.6 | 32.0 | 17.3 | 41.7 | 100.0 | — |
SOLV — Pillar Breakdown
Quality
— 68.8/100 (25%)Solventum Corporation shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 17.8/100 (20%)Solventum Corporation faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 39.2/100 (15%)Solventum Corporation has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 91.3/100 (15%)Solventum Corporation appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
Enterprise value multiple relative to sector median.
Moat
— 32/100 (25%)Solventum Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SOLV.
Score Composition
Financial Data
More Stock Analysis
How is the SOLV UQS Score Calculated?
The UQS (Unified Quality Score) for Solventum Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Solventum Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Solventum Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.